HDL-C and HDL-C/ApoA-I predict long-term progression of glycemia in established type 2 diabetes

Diabetes Care

Volumn 37, Issue 8, 2014, Pages 2351-2358

  Waldman, Boris ^a   Jenkins, Alicia J ^a   Davis, Timothy M E ^b   Taskinen, Marja Riitta ^c   Scott, Russell ^d   O'Connell, Rachel L ^a   Gebski, Val J ^a   Ng, Martin K C ^e   Keech, Anthony C ^a,e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d CHRISTCHURCH HOSPITAL   (New Zealand)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; FENOFIBRATE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; B LYMPHOCYTE; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROTEIN ANALYSIS; PROTEIN FUNCTION; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; AGED; ANALYSIS; BLOOD; CROSS-SECTIONAL STUDY; DIABETES MELLITUS, TYPE 2; FOLLOW UP; METABOLISM; MIDDLE AGED; PANCREAS ISLET BETA CELL; PHYSIOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; APOLIPOPROTEIN A-I; BLOOD GLUCOSE; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; FENOFIBRATE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME;

EID: 84905053637     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2738     Document Type: Article

References (40)

1. Festa A, Williams K, D'Agostino R Jr, Wagenknecht LE, Haffner SM. The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes 2006; 55: 1114-1120
2. Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care 2009; 32(Suppl. 2): S151-S156
3. Grant RW, Meigs JB Prevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes: an unmet challenge for cardiovascular risk reduction. Diabetes Care 2007; 30: 479-484
4. Klein BEK, Klein R, Lee KE Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care 2002; 25: 1790-1794
5. Turner RC, Millns H, Neil HAW, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823-828
6. Haffner SM, Stern MP, Hazuda H.P., Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990; 263: 2893-2898
7. Mykkänen L., Kuusisto J, Pyörälä K, Laakso M. Cardiovascular disease risk factors as predictors of type 2 (non-insulin- dependent) diabetes mellitus in elderly subjects. Diabetologia 1993; 36: 553-559
8. Abbasi A, Corpeleijn E, Gansevoort R.T., et al. Role of HDL cholesterol and estimates of HDL particle composition in future development of type 2 diabetes in the general population: the PREVEND study. J Clin Endocrinol Metab 2013; 98: E1352-E1359
9. Festa A, Williams K, Hanley AJG, et al. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation 2005; 111: 3465-3472
10. Mora S, Otvos JD, Rosenson R.S., Pradhan A., Buring JE, Ridker PM. Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes 2010; 59: 1153-1160
11. D'Agostino RB Jr, Hamman RF, Karter AJ, Mykkanen L, Wagenknecht LE, Haffner SM; Insulin Resistance Atherosclerosis Study Investigators. Cardiovascular disease risk factors predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes Care 2004; 27: 2234-2240
12. Hodge AM, Jenkins AJ, English D.R., O'Dea K, Giles GG. NMR-determined lipoprotein subclass profile predicts type 2 diabetes. Diabetes Res Clin Pract 2009; 83: 132-139
13. Rütti S., Ehses JA, Sibler R.A., et al. Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology 2009; 150: 4521-4530
14. Drew BG, Rye KA, Duffy S.J., Barter P., Kingwell BA. The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol 2012; 8: 237-245
15. Brunham LR, Kruit JK, Pape T.D., et al. Betacell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 2007; 13: 340-347
16. Han R, Lai R, Ding Q., et al. Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolism. Diabetologia 2007; 50: 1960-1968
17. Dullaart RPF, Annema W, de Boer JF, Tietge UJ. Pancreatic β-cell function relates positively to HDL functionality in well-controlled type 2 diabetes mellitus. Atherosclerosis 2012; 222: 567-573
18. Drew BG, Duffy SJ, Formosa M.F., et al. Highdensity lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 2009; 119: 2103-2111
19. Ahmad Khan H. Clinical significance of HbA1c as a marker of circulating lipids in male and female type 2 diabetic patients. Acta Diabetol 2007; 44: 193-200
20. Gatti A, Maranghi M, Bacci S., et al. Poor glycemic control is an independent risk factor for low HDL cholesterol in patients with type 2 diabetes. Diabetes Care 2009; 32: 1550-1552
21. Mazer NA, Giulianini F, Paynter N.P., Jordan P., Mora S. A comparison of the theoretical relationship between HDL size and the ratio of HDL cholesterol to apolipoprotein A-I with experimental results from the Women's Health Study. Clin Chem 2013; 59: 949-958
22. Barter P, Best J, Colman P., et al.; FIELD Study Investigators. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]. Cardiovasc Diabetol 2004; 3: 9
23. Best JD, Drury PL, Davis T.M., et al.; Fenofibrate Intervention and Event Lowering in Diabetes Study Investigators. Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort. Diabetes Care 2012; 35: 1165-1170
24. Matthews DR, Hosker JP, Rudenski A.S., Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and betacell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
25. Calculator HOMA. HOMA Calculator FAQ [Internet], 2014. Available from http://www.dtu.ox.ac.uk/homacalculator/FAQ.php. Accessed 2 April 2014
26. Scott R, Best J, Forder P., et al.; FIELD Study Investigators. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovasc Diabetol 2005; 4: 13
27. Prentki M, Nolan CJ Islet b cell failure in type 2 diabetes. J Clin Invest 2006; 116: 1802-1812
28. Goldberg RB, Temprosa M, Haffner S., et al.; Diabetes Prevention Program Research Group. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group. Diabetes Care 2009; 32: 726-732
29. Pani LN, Nathan DM, Grant RW Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1C less than 7%. Diabetes Care 2008; 31: 386-390
30. Supplement 1. American Diabetes Association: clinical practice recommendations 2000. Diabetes Care 2000; 23(Suppl. 1): S1-S116
31. Roussell MA, Kris-Etherton P. Effects of lifestyle interventions on high-density lipoprotein cholesterol levels. J Clin Lipidol 2007; 1: 65-73
32. Slagter SN, van Vliet-Ostaptchouk JV, Vonk JM, et al. Associations between smoking, components of metabolic syndrome and lipoprotein particle size. BMC Med 2013; 11: 195
33. Haffner SM, D'Agostino R Jr, Mykkänen L, et al. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 1999; 22: 562-568
34. Leinonen E, Hurt-Camejo E, Wiklund O., Hultén LM, Hiukka A., Taskinen MR. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis 2003; 166: 387-394
35. Lupi R, Dotta F, Marselli L, et al. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that β-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes 2002; 51: 1437-1442
36. Garvey WT, Kwon S, Zheng D., et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003; 52: 453-462
37. Kontush A, Chapman MJ Why is HDL functionally deficient in type 2 diabetes? Curr Diab Rep 2008; 8: 51-59
38. Yvan-Charvet L., Wang N, Tall AR Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol 2010; 30: 139-143
39. Wallace TM, Levy JC, Matthews DR Useand abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495
40. Morton J, Zoungas S, Li Q., et al.; ADVANCE Collaborative Group. Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study. Diabetes Care 2012; 35: 2201-2206